Activaero GmbH / ACTIVAERO PROVIDES UPDATE ON Q4 2013 PARTNERING ACTIVITIES . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. * RESEARCH AGREEMENTS SIGNED WITH TWO LEADING PHARMACEUTICAL PLAYERS AND IMPORTANT EUROPEAN SPECIALTY PHARMA COMPANY * NEW DEVELOPMENT AND LICENSE AGREEMENT WITH PARION SCIENCES Gemuenden/Wohra, Germany, January 10, 2014 - Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions for severe lung diseases, today provided an update on its partnering activities in Q4 2013. Towards the end of the year, the Company signed two research agreements, with one of the Top10 pharmaceutical companies and with a major European Specialty Pharma company. In addition, Activaero entered into a development collaboration with another Top20 pharmaceutical firm. Details of the agreements are not disclosed. Finally, in October 2013, the respiratory area specialist has entered into a development and license agreement with Parion Sciences Inc., a privately-held US pharmaceutical company focusing on the discovery and development of pulmonary and ophthalmology therapeutics. Under the terms of the agreement, Activaero will grant Parion an exclusive, worldwide license to certain parts of its proprietary FAVORITE inhalation approach including a unique, high efficiency aerosol generator. Activaero's aerosol generator will be customized and integrated into Parion's transnasal pulmonary aerosol delivery ("tPAD") system. The tPAD system pairs the Activaero technology with Parion's proprietary therapeutic agents and delivery device advancing the commercialization of combination products. In return, Activaero will be eligible to receive an undisclosed upfront payment, regulatory milestone payments and royalties. Bernhard Müllinger, Chief Technical Officer of Activaero GmbH, commented: "Currently, off-the-shelf inhalation devices carry significant disadvantages for payers and patients. These devices force patients to inhale too fast resulting in non-reproducible, inefficient inhalation maneuvers. Consequently, high amounts of inhaled substance are deposited in the throat. These deposits are not only wasted but also cause local irritations and side effects. With our FAVORITE approach we can create safe and effective, pharmacoeconomically meaningful aerosol-based therapies that are delivered into the lung with an unparalleled consistency and lung deposition rates of more than 80%." "The tPAD system's unique, slow aerosol infusion represents a paradigm shift in nebulized delivery that aims to improve patients' quality of life in terms of convenience, efficacy and tolerability." explains Paul Boucher, VP, Finance and Business of Parion Sciences Inc. "We are delighted to partner with Activeaero's expert team to integrate the proven, consistent and efficient aerosolization capabilities of the FAVORITE approach to optimize the therapeutic potential of the tPAD system." About FAVORITE FAVORITE is Activaero's proprietary, clinically and commercially proven inhalation approach to effectively treat severe respiratory and pulmonary diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By guiding, controlling and supporting the patient's breathing, optimal inhalation patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted to pre-defined lung regions hence unlocking completely new opportunities for novel aerosol therapies. About Activaero Activaero is a therapeutic area specialist developing new, pharmacoeconomically meaningful treatment solutions for patients suffering from severe respiratory diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension. Activaero was founded in 1998 in Germany and is a privately held company with offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA). About tPAD The tPAD platform is designed to administer aerosolized medicines overnight via transnasal application, shifting the patient's treatment burden away from day time hours to periods during sleep. Its aerosol characteristics have been optimized to efficiently deliver medication through a nasal cannula, bypassing the nasal passages and depositing a high percentage into the lungs under natural breathing. About Parion Based in Durham, NC, Parion Sciences is a privately-held, development-stage pharmaceutical company that is leveraging its proprietary small molecule chemistry and epithelial biology expertise to discover and develop an innovative pipeline of therapies for diseases resulting from the failure of the body's mucosal defenses, including chronic obstructive pulmonary disorder (COPD), cystic fibrosis, bronchiectasis and dry eye disease. For more information, please visit Contact us: Activaero GmbH Media Contact Christian Pangratz Anne Hennecke Chief Business Officer MC Services AG t: +49-89-897969-65 t: +49-89-210228-18 e: e: Press release (PDF) : This announcement is distributed by GlobeNewswire on behalf of GlobeNewswire clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Activaero GmbH via GlobeNewswire [HUG#1753852]